HYPERION DEFI, INC. Annual Performance Review

I’ve put together this guide to help you understand how Hyperion DeFi, Inc. performed this year. The company has transitioned from a medical-tech firm into a hybrid business focused on the crypto sector.

1. What does this company do?

Hyperion DeFi operates two distinct businesses. They maintain assets related to the "Optejet" eye-care device, which delivers eye medication in micro-doses. Simultaneously, they have pivoted to become a participant in the "Hyperliquid" blockchain ecosystem. They hold the native token (HYPE) and operate their own validator, "Kinetiq x Hyperion." This node processes blockchain transactions to earn fees, and they "stake" their HYPE holdings to secure the network in exchange for rewards.

2. Financial Performance & Health

The company is currently in a capital-intensive phase, spending more cash than it generates from operations.

• The Cash Situation: The company reported a $42.5 million loss last year. With $8.2 million in cash remaining, they rely on selling new shares and utilizing debt financing to maintain operations.
• The "HYPE" Strategy: Financial health is tied to the HYPE token. They hold over 11 million tokens, which are subject to a seven-day "unbonding" period. This means these assets cannot be liquidated instantly to cover immediate liabilities.
• Debt: They hold loans with Avenue Capital. These agreements have been modified four times in 18 months, resulting in delayed payments and interest rates rising to 12%.

3. Major Wins and Challenges

• Wins: The "Kinetiq x Hyperion" validator has attracted over 11 million HYPE tokens, establishing it as a significant node. The company is currently marketing "HYPE-as-a-service" to institutional clients, aiming to generate management fees that are independent of token price volatility.
• Challenges: The company is heavily invested in the Hyperliquid ecosystem, which operates in an evolving regulatory environment. Meanwhile, the Optejet medical device business requires approximately $2.5 million in quarterly funding and is not yet self-sustaining.

4. Key Risks

• The "HYPE" Gamble: A significant portion of the company’s value is linked to the HYPE token; a decline in the token price would directly impact the balance sheet. Additionally, the SEC has not provided definitive guidance on whether their staking service qualifies as an unregistered security.
• Dilution: To offset the $42.5 million loss, the company issued 15 million new shares last year, which reduced existing shareholder ownership by approximately 22%.
• Delisting Risk: The stock frequently trades below the $1.00 Nasdaq requirement. If the price remains below this threshold for 30 consecutive days, the stock risks being delisted and moved to OTC markets, which would impact liquidity.

5. Future Outlook

Management is shifting focus away from medical devices to become a dedicated DeFi provider. The stated goal is to reach a break-even point by the end of next year through validator fees and staking rewards. However, the company notes that they expect to continue incurring losses and that long-term profitability is contingent upon the growth and stability of the Hyperliquid ecosystem.

---

Investor Takeaway: Hyperion DeFi is a high-risk, speculative play. You are essentially betting on the success of the Hyperliquid blockchain and the company's ability to pivot away from its legacy medical business before its current cash reserves are exhausted. Before investing, consider whether you are comfortable with the potential for further share dilution and the volatility inherent in the crypto-staking market.